SBI Debt Fund Series B 28 1100 Days Announces Maturity

November 27th, 2018

SBI Mutual Fund has announced SBI Debt Fund Series B - 28 (1100 Days) will mature on 30 November 2018 and accordingly, units of the scheme shall be suspended from trading from the respective stock exchange.

0 thoughts on “SBI Debt Fund Series B 28 1100 Days Announces Maturity”

Post Comment

Comment

Full name

Email address

Mobile

Daily News

VIEW ALL

BSE NSE halt trading for 1st time in 12 years Circuit breaker limit explained

-March 13th, 2020

Yes Bank inward RTGS enabled to receive payments

-March 12th, 2020

Nifty 50 may slip below 10000 mark as WHO calls coronavirus a pandemic

-March 12th, 2020

Yes Bank enables inward IMPS NEFT transactions

-March 11th, 2020

COVID19 oil prices pulls down RILs refining chemical valuation by $7 billion

-March 11th, 2020

Jet Airways Committee of Creditors to meet on Thursday

-March 11th, 2020

Investor euphoria punctured as Maruti disappoints on operating performance

-January 29th, 2020

Sumitomo Indias MNC parentage will count if profitability improves

-January 29th, 2020

Sumitomo Indias MNC parentage will count if profitability improves

-January 29th, 2020

Stocks to Watch DHFL InterGlobe Aviation HDFC Godfrey Phillips Torrent Pharma

-January 28th, 2020

Jio largest in revenue customers base India Ratings

-January 28th, 2020

Axis Bank delivers on growth but trouble lingers on the bad loans front

-January 23rd, 2020

Asian Paints revenue growth dims in Q3 but profit margins stay bright

-January 23rd, 2020

HDFC AMC clocks a steady Q3 but the stock remains pricey

-January 23rd, 2020

Vodafone Idea stocks jumps 20% over SC relief

-January 22nd, 2020

ICICI Pru Lifes profitability metrics impress but biz growth yet to cut ice

-January 22nd, 2020

ITIs Rs 1600cr FPO to open on Friday

-January 21st, 2020

Reality check for Kotak Bank stock as growth slows and slippages rise

-January 21st, 2020

NSE promoted PXIL develops real time power market with PRATYAY

-January 21st, 2020

Why investors doubt the logic behind Biocon Biologics deal valuation

-January 7th, 2020